This genomics stock appears to be at an inflection point.Guardant Health (GH +0.68%) is on the rise, in more ways than one. Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several key victories recently, including signing a multi-year collaboration with Merck (MRK +1.35%) to develop companion diagnostics and market new cancer therapies with Guardant's Infinity Smart program. Although Guardant Health hasn't announced a date for releasing ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military's health insurance coverage, with no copay for average-risk individuals ages 45 and older. Shield is the first and only blood test approved by the FDA as a primary screening option for CRC, offering U.S. military. ...